Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from a sell rating to a hold rating in a research note published on Tuesday morning, BidAskClub reports.

Other equities analysts also recently issued reports about the company. Cantor Fitzgerald reissued a buy rating on shares of Halozyme Therapeutics in a research report on Wednesday, May 8th. Zacks Investment Research downgraded Halozyme Therapeutics from a buy rating to a hold rating in a research report on Thursday, April 25th. ValuEngine downgraded Halozyme Therapeutics from a buy rating to a hold rating in a research report on Wednesday, March 6th. TheStreet downgraded Halozyme Therapeutics from a c rating to a d rating in a research report on Tuesday, March 5th. Finally, JMP Securities reissued a buy rating and issued a $21.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, February 27th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $20.40.

NASDAQ HALO opened at $15.73 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.72 and a current ratio of 2.95. Halozyme Therapeutics has a 1 year low of $13.24 and a 1 year high of $19.56. The firm has a market capitalization of $2.25 billion, a P/E ratio of -28.09 and a beta of 1.77.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. Halozyme Therapeutics had a negative return on equity of 20.36% and a negative net margin of 28.70%. The firm had revenue of $56.95 million for the quarter, compared to the consensus estimate of $67.80 million. During the same period in the prior year, the firm earned ($0.19) EPS. The firm’s revenue was up 84.3% on a year-over-year basis. On average, analysts expect that Halozyme Therapeutics will post -0.42 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HALO. Marshall Wace North America L.P. acquired a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at about $1,053,000. Marshall Wace LLP acquired a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at about $740,000. FMR LLC grew its position in shares of Halozyme Therapeutics by 5.0% during the 1st quarter. FMR LLC now owns 2,685,575 shares of the biopharmaceutical company’s stock valued at $43,238,000 after acquiring an additional 127,379 shares during the period. HighTower Advisors LLC grew its position in shares of Halozyme Therapeutics by 3.5% during the 1st quarter. HighTower Advisors LLC now owns 29,629 shares of the biopharmaceutical company’s stock valued at $476,000 after acquiring an additional 1,014 shares during the period. Finally, Schonfeld Strategic Advisors LLC grew its position in shares of Halozyme Therapeutics by 667.7% during the 1st quarter. Schonfeld Strategic Advisors LLC now owns 176,576 shares of the biopharmaceutical company’s stock valued at $2,844,000 after acquiring an additional 153,576 shares during the period. 82.08% of the stock is currently owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Featured Article: Recession

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.